Patient Advocates Meet with Legislators Read more about Patient Advocates Meet with LegislatorsAdd new comment
International Myeloma Foundation Holds 15th Annual Gala at the Edison Ballroom in New York City on April 18 Read more about International Myeloma Foundation Holds 15th Annual Gala at the Edison Ballroom in New York City on April 18 Add new comment
European Commission Approves CARVYKTI (Cilta-Cel) for Relapsed and Refractory Multiple Myeloma Patients Who Have Received At Least One Prior Line of Therapy Read more about European Commission Approves CARVYKTI (Cilta-Cel) for Relapsed and Refractory Multiple Myeloma Patients Who Have Received At Least One Prior Line of TherapyAdd new comment
International Myeloma Foundation Celebrates ODAC Meeting Outcome on Minimal Residual Disease (MRD) Testing as an Early Endpoint for the Accelerated Approval of Myeloma Drugs in Clinical Trials: A Huge Win for the Global Myeloma Community. Read more about International Myeloma Foundation Celebrates ODAC Meeting Outcome on Minimal Residual Disease (MRD) Testing as an Early Endpoint for the Accelerated Approval of Myeloma Drugs in Clinical Trials: A Huge Win for the Global Myeloma Community. Add new comment
The International Myeloma Foundation and Black Swan Research Initiative® Announce the Release of New iStopMM Cohort Study: A Multivariable Prediction Model for Bone Marrow Sampling on Individuals with MGUS Read more about The International Myeloma Foundation and Black Swan Research Initiative® Announce the Release of New iStopMM Cohort Study: A Multivariable Prediction Model for Bone Marrow Sampling on Individuals with MGUS Add new comment
FDA Approves CARVYKTI (ciltacabtagene autoleucel; cilta-cel) for Relapsed or Refractory Multiple Myeloma Patients Who Have Received at Least One Prior Line of Therapy Read more about FDA Approves CARVYKTI (ciltacabtagene autoleucel; cilta-cel) for Relapsed or Refractory Multiple Myeloma Patients Who Have Received at Least One Prior Line of TherapyAdd new comment
FDA Approves Abecma for Triple-Class Exposed Relapsed or Refractory Multiple Myeloma After Two Prior Lines of Therapy Read more about FDA Approves Abecma for Triple-Class Exposed Relapsed or Refractory Multiple Myeloma After Two Prior Lines of TherapyAdd new comment
Over 52 Million Myeloma Warriors Reached, Creating Ripples Across the Globe for #MyelomaACTIONMonth! Read more about Over 52 Million Myeloma Warriors Reached, Creating Ripples Across the Globe for #MyelomaACTIONMonth!Add new comment
March 2024 – Myeloma News from the Journals Read more about March 2024 – Myeloma News from the JournalsAdd new comment
